Loading...
Loading...
ABIO| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 12.0K |
| Gross Profit | -12.0K |
| Operating Expense | 2,740.0K |
| Operating I/L | -2,752.0K |
| Other Income/Expense | 74.0K |
| Interest Income | 444.0K |
| Pretax | -2,678.0K |
| Income Tax Expense | 0.0K |
| Net Income/Loss | -2,678.0K |
ARCA biopharma, Inc. is a clinical-stage biopharmaceutical company specializing in genetically targeted therapies for cardiovascular diseases. Its lead product candidates include rNAPc2 (AB201), currently in Phase IIb clinical trial for COVID-19 treatment, and Gencaro (bucindolol hydrochloride), a beta-adrenergic receptor antagonist that has completed Phase IIb trial for atrial fibrillation in chronic heart failure patients. The company generates revenue through the development and commercialization of these genetically targeted therapies, including collaborations with LabCorp for genetic testing and research collaboration with the Colorado Prevention Center and the University of Colorado's Academic Research Organization for Gencaro.
